Alopecia Therapeutics - A Pipeline Analysis Report

This pipeline analysis report provides detailed insights into the clinical trials landscape of the drug development for alopecia therapeutics including molecules at pre-clinical and discovery stage. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentation such as therapy, route of administration, and target.

Overview of the drug development pipeline for alopecia therapeutics

It has been observed that alopecia is an autoimmune disorder that results in unpredictable hair loss from the scalp, face, and sometimes elsewhere in the body. In most cases, hair loss occurs in small patches, while in some cases, hair loss is extreme. The common types of alopecia are alopecia areata, androgenetic alopecia, alopecia totalis, and alopecia universalis. The main symptom of alopecia is hair loss. Hair loss usually falls out in small round patches. These patches are generally of several centimeters. The primary cause of alopecia is the immune system attacking healthy hair follicles. Also, people with a family history of type 1 diabetes and rheumatoid arthritis are more prone to alopecia. According to the National Institute of Health (NIH), androgenetic alopecia is one of the most frequent causes of hair loss and affects more than 50 million men and 30 million women in the US. Monotherapy is emerging as the most efficient approach to the treatment of alopecia.

According to this pipeline analysis report, most of the drug molecules in the pipeline are being developed for alopecia. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

Want a bigger picture? Try a FREE sample of this report now!

Drug development pipeline report for alopecia therapeutics: Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of alopecia. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are

• Aclaris Therapeutics
• Allergan
• BiologicsMD

Therapeutic assessment of the drug development pipeline for alopecia therapeutics by route of administration

• Topical
• Oral
• Intradermal
• Unknown

The topical route of administration (ROA) involves the application of the drug directly onto the skin surface and in the oral technique, the molecules are delivered directly into the mouth cavity, which will have a more direct effect on the target cells.

Therapeutic assessment of the drug development pipeline for alopecia therapeutics by therapy

• Monotherapy
• Combination therapy
• Unknown

According to this pipeline analysis report, most of the molecules that are currently in the drug pipeline for alopecia therapeutics are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.

Key questions answered in the report include

• What are the gene therapy molecules in the various development stages for alopecia therapeutics?
• What are the companies that are currently involved in the development of drug molecules for alopecia therapeutics?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.